Recipharm Announces Signature of Letter of Intent for Aseptic Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate

Recipharm, a leading contract development and manufacturing organization (CDMO), recently announced that it has signed a letter of intent with Moderna, a US-based biotech company, to formulate, fill, and finish mRNA-1273, Moderna’s COVID-19 vaccine candidate. The activity will be performed in Recipharm’s drug product manufacturing facility located in Monts, France. Recipharm has reserved capacity to support the anticipated demand for the vaccine and is already in the process of recruiting additional staff and making certain investments to enable technology transfer and scale-up to commence imminently.

Thomas Eldered, CEO of Recipharm, said “We are delighted to be working with Moderna on this vital project in order to support the fight against COVID-19. Our operations in France are ideally suited to perform this work by combining our technical and operational know-how to deliver high-quality pharmaceutical manufacture of biologics with a challenging timeline. We anticipate that the final agreement will be finalized during December.”

Recipharm is a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development, and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information, visit